Protein C Sapporo (protein C Glu 25 → Lys): A heterozygous missense mutation in the Gla domain provides new insight into the interaction between protein C and endothelial protein C receptor

Summary Interaction of the γ-carboxyglutamic acid (Gla) domain of protein C with endothelial protein C receptor (EPCR) is a critical step for efficient activation of protein C, though interactions by mutants in the Gla domain of protein C with EPCR have been rarely evaluated. We identified a 44-year-old Japanese woman with a history of recurrent thromboembolism as an inherited missense mutation, the first such case reported in Japan, which involved a protein C Gla 25 mutation. Total protein C antigen and Gla protein C antigen levels in the proband were normal. Protein C activity measured with an anticoagulant assay was reduced, whereas that measured with an amidolytic assay was normal. She was therefore phenotypically diagnosed as type IIb protein C deficiency. Direct sequencing of the PCR fragments revealed a heterozygous G toA transition at nucleotide position 1462 in exon 3, which predicted an amino acid substitution of Glu 25 by Lys. Her mother and one son were also heterozygous for this mutation. A molecular dynamics simulation of Gla 25→Lys/EPCR complex in water suggested that the affinity between the molecules was decreased compared to the wild type Gla domain/EPCR complex. Since Gla 25 has been shown to play an important role in protein C function, not only in membrane phospholipid binding but also in binding to EPCR, our findings provide new insight into the mechanism by which the Glu 25→Lys mutation induces type IIb protein C deficiency in individuals.

[1]  S. Eichinger,et al.  Deep vein thrombosis , 2005, The Lancet.

[2]  B. Dahlbäck,et al.  Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation , 2004, The FEBS journal.

[3]  F R Rosendaal,et al.  Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis , 2004, Journal of thrombosis and haemostasis : JTH.

[4]  Justo Aznar,et al.  Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk , 2004, Thrombosis and Haemostasis.

[5]  N. Hamasaki,et al.  Identification of simultaneous mutation of fibrinogen α chain and protein C genes in a Japanese kindred , 2003, British journal of haematology.

[6]  K. Amano,et al.  Two double heterozygous mutations in the F7 gene show different manifestations , 2002, British journal of haematology.

[7]  K. Kottke-Marchant,et al.  Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor. , 2002, Archives of pathology & laboratory medicine.

[8]  N. Sakuragi,et al.  Thromboprophylaxis with low molecular weight heparin in thrombophilia‐complicated pregnancy , 2002, The journal of obstetrics and gynaecology research.

[9]  Zbigniew Dauter,et al.  The Crystal Structure of the Endothelial Protein C Receptor and a Bound Phospholipid* , 2002, The Journal of Biological Chemistry.

[10]  A. D’Angelo,et al.  Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. , 2002, Blood.

[11]  G. Palù,et al.  Abnormal Propeptide Processing Resulting in the Presence of Two Abnormal Species of Protein C in Plasma , 2001, Thrombosis and Haemostasis.

[12]  C. Esmon,et al.  Endothelial cell protein C receptor plays an important role in protein C activation in vivo. , 2001, Blood.

[13]  F. Rosendaal,et al.  High levels of factor IX increase the risk of venous thrombosis. , 2000, Blood.

[14]  C. Esmon,et al.  The Endothelial Cell Protein C Receptor , 2000, Thrombosis and Haemostasis.

[15]  F. Rosendaal,et al.  High levels of coagulation factor XI as a risk factor for venous thrombosis. , 2000, The New England journal of medicine.

[16]  C. Esmon,et al.  Mechanisms by Which Soluble Endothelial Cell Protein C Receptor Modulates Protein C and Activated Protein C Function* , 2000, The Journal of Biological Chemistry.

[17]  Mannucci,et al.  Type II protein C deficiency: identification and molecular modelling of two natural mutants with low anticoagulant and normal amidolytic activity , 2000, British journal of haematology.

[18]  B. Furie,et al.  Vitamin K-Dependent Biosynthesis of γ-Carboxyglutamic Acid , 1999 .

[19]  H. Blom,et al.  Hyperhomocysteinemia and Venous Thrombosis: A Meta-analysis , 1998, Thrombosis and Haemostasis.

[20]  K. Fukudome,et al.  Activation Mechanism of Anticoagulant Protein C in Large Blood Vessels Involving the Endothelial Cell Protein C Receptor , 1998, The Journal of experimental medicine.

[21]  M. D'ambra,et al.  Intrinsic Anticoagulation: Protein C, Protein S, and Thrombomodulin , 1997 .

[22]  C. Esmon,et al.  The Interaction between the Endothelial Cell Protein C Receptor and Protein C Is Dictated by the γ-Carboxyglutamic Acid Domain of Protein C* , 1997, The Journal of Biological Chemistry.

[23]  P. Reitsma Protein C Deficiency: from Gene Defects to Disease , 1997, Thrombosis and Haemostasis.

[24]  W. Kisiel,et al.  Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. , 1997, Biochemistry.

[25]  D. Lane,et al.  Gene Mutations in 21 Unrelated Cases of Phenotypic Heterozygous Protein C Deficiency and Thrombosis , 1996, Thrombosis and Haemostasis.

[26]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[27]  M. Aiach,et al.  Molecular basis for protein C hereditary deficiency. , 1996, Haemostasis.

[28]  C. Esmon,et al.  The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Castellino,et al.  Binding of calcium to individual gamma-carboxyglutamic acid residues of human protein C. , 1995, Biochemistry.

[30]  J. Emmerich,et al.  Influence of Six Mutations of the Protein C Gene on the Gla Domain Conformation and Calcium Affinity , 1994, Thrombosis and Haemostasis.

[31]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[32]  J. Griffin,et al.  Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three‐dimensional molecular modelling of mutations of the protease domain , 1994, Proteins.

[33]  Tatsuya Hayashi,et al.  A Compound Heterozygous Protein C Deficiency with a Single Nucleotide G Deletion Encoding Gly-381 and an Amino Acid Substitution of Lys for Gla-26 , 1993, Thrombosis and Haemostasis.

[34]  M. Vidaud,et al.  Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis , 1993, British journal of haematology.

[35]  F. Castellino,et al.  Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. , 1992, Blood.

[36]  R. Marlar,et al.  Hereditary Dysfunctional Protein C Molecules (Type II): Assay Characterization and Proposed Classification , 1990, Thrombosis and Haemostasis.

[37]  A A Connolly,et al.  Deep vein thrombosis. , 1988, BMJ.

[38]  Y. Sakata,et al.  Conformation-specific monoclonal antibodies to the calcium-induced structure of protein C. , 1986, The Journal of biological chemistry.

[39]  G. Crabtree,et al.  Evolution and organization of the human protein C gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Davie,et al.  The nucleotide sequence of the gene for human protein C. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Katz,et al.  INHERITED PROTEIN C DEFICIENCY AND COUMARIN-RESPONSIVE CHRONIC RELAPSING PURPURA FULMINANS IN A NEWBORN INFANT , 1983, The Lancet.

[42]  J. Griffin,et al.  Deficiency of protein C in congenital thrombotic disease. , 1981, The Journal of clinical investigation.

[43]  P. Simioni,et al.  Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. , 2006, Thrombosis research.

[44]  J. Reny,et al.  Hemostasis, Thrombosis, and Vascular Biology , 2022 .

[45]  E. Persson Ca 2+ Binding to Proteins Containing γ-Carboxyglutamic Acid Residues , 2002 .

[46]  P. Reitsma,et al.  High Plasma Concentration of Factor VIIIc Is a Major Risk Factor for Venous Thromboembolism , 2000, Thrombosis and Haemostasis.

[47]  M. Aiach,et al.  Thirty-three Novel Mutations in the Protein C Gene , 2000, Thrombosis and Haemostasis.

[48]  H. Watzke,et al.  Factor X Frankfurt I: molecular and functional characterization of a hereditary factor X deficiency (Gla+25 to Lys). , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[49]  B. Dahlbäck The protein C anticoagulant system: inherited defects as basis for venous thrombosis. , 1995, Thrombosis research.

[50]  N. Tsushima,et al.  Three Missense Mutations in the Protein C Heavy Chain Causing Type I and Type II Protein C Deficiency , 1994, Thrombosis and Haemostasis.

[51]  Triplett Da,et al.  Clinical application of a functional assay for protein C. , 1987 .

[52]  D. Triplett,et al.  Clinical application of a functional assay for protein C. , 1987, Hematologic pathology.